Michael Liu, Sarah Huang, Masataka Kawana, Matthew T Wheeler, Victoria Parikh, Marco V Perez
{"title":"Distinct mechanistic features of atrial fibrillation in hypertrophic cardiomyopathy.","authors":"Michael Liu, Sarah Huang, Masataka Kawana, Matthew T Wheeler, Victoria Parikh, Marco V Perez","doi":"10.1016/j.hrthm.2026.03.1958","DOIUrl":null,"url":null,"abstract":"<p><p>Atrial fibrillation (AF) in hypertrophic cardiomyopathy (HCM) is increasingly recognized as a distinct clinical entity, characterized by early onset, high prevalence, and uniquely poor outcomes compared with AF in the general population. This review synthesized emerging evidence on the genetic, molecular, and hemodynamic mechanisms underlying AF-HCM. Patients with AF-HCM face a dramatically increased risk of stroke and heart failure, independent of conventional risk stratification tools, necessitating universal anticoagulation and aggressive rhythm control. Current therapies including cardiac ablation and antiarrhythmic drugs demonstrate limited efficacy and/or safety in this population. Recent clinical trials and real-world studies reveal persistent AF incidence despite advances in HCM management, underscoring the need for novel, disease-specific therapeutic strategies. AF-HCM exemplifies the importance of genotype-driven precision medicine in cardiology and highlights ongoing gaps in the treatment of complex inherited arrhythmias.</p>","PeriodicalId":12886,"journal":{"name":"Heart rhythm","volume":" ","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart rhythm","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.hrthm.2026.03.1958","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Atrial fibrillation (AF) in hypertrophic cardiomyopathy (HCM) is increasingly recognized as a distinct clinical entity, characterized by early onset, high prevalence, and uniquely poor outcomes compared with AF in the general population. This review synthesized emerging evidence on the genetic, molecular, and hemodynamic mechanisms underlying AF-HCM. Patients with AF-HCM face a dramatically increased risk of stroke and heart failure, independent of conventional risk stratification tools, necessitating universal anticoagulation and aggressive rhythm control. Current therapies including cardiac ablation and antiarrhythmic drugs demonstrate limited efficacy and/or safety in this population. Recent clinical trials and real-world studies reveal persistent AF incidence despite advances in HCM management, underscoring the need for novel, disease-specific therapeutic strategies. AF-HCM exemplifies the importance of genotype-driven precision medicine in cardiology and highlights ongoing gaps in the treatment of complex inherited arrhythmias.
期刊介绍：
HeartRhythm, the official Journal of the Heart Rhythm Society and the Cardiac Electrophysiology Society, is a unique journal for fundamental discovery and clinical applicability.
HeartRhythm integrates the entire cardiac electrophysiology (EP) community from basic and clinical academic researchers, private practitioners, engineers, allied professionals, industry, and trainees, all of whom are vital and interdependent members of our EP community.
The Heart Rhythm Society is the international leader in science, education, and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education, and optimal health care policies and standards.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
